M F Sanmamed1, J L Perez-Gracia2,3, K A Schalper4,5, J P Fusco2, A Gonzalez3,6, M E Rodriguez-Ruiz2,7, C Oñate2, G Perez2, C Alfaro2,3, S Martín-Algarra2, M P Andueza2, A Gurpide2, M Morgado4, J Wang1, A Bacchiocchi8, R Halaban8, H Kluger5, L Chen1, M Sznol5, I Melero2,6,7. 1. Department of Immunobiology, Yale University School of Medicine, New Haven, USA. 2. Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain. 3. CIBERONC (Centro de Investigación Biomedica en Red de Cáncer). 4. Department of Pathology, Yale University School of Medicine, New Haven, CT, USA. 5. Comprehensive Cancer Center Section of Medical Oncology, Yale University School of Medicine, New Haven, CT, USA. 6. Department of Biochemistry, Clínica Universidad de Navarra, Pamplona, Spain. 7. Centro de Investigación Biomédica en Red de Oncología (CIBERONC), Spain. 8. Department of Dermatology, Yale University School of Medicine, New Haven, USA.
Abstract
BACKGROUND: Surrogate biomarkers of efficacy are needed for anti-PD1/PD-L1 therapy, given the existence of delayed responses and pseudo-progressions. We evaluated changes in serum IL-8 levels as a biomarker of response to anti-PD-1 blockade in melanoma and non-small-cell lung cancer (NSCLC) patients. PATIENTS AND METHODS: Metastatic melanoma and NSCLC patients treated with nivolumab or pembrolizumab alone or nivolumab plus ipilimumab were studied. Serum was collected at baseline; at 2-4 weeks after the first dose; and at the time-points of response evaluation. Serum IL-8 levels were determined by sandwich ELISA. Changes in serum IL-8 levels were compared with the Wilcoxon test and their strength of association with response was assessed with the Mann-Whitney test. Accuracy of changes in IL-8 levels to predict response was estimated using receiver operation characteristics curves. RESULTS: Twenty-nine melanoma patients treated with nivolumab or pembrolizumab were studied. In responding patients, serum IL-8 levels significantly decreased between baseline and best response (P <0.001), and significantly increased upon progression (P = 0.004). In non-responders, IL-8 levels significantly increased between baseline and progression (P = 0.013). Early changes in serum IL-8 levels (2-4 weeks after treatment initiation) were strongly associated with response (P <0.001). These observations were validated in 19 NSCLC patients treated with nivolumab or pembrolizumab (P = 0.001), and in 15 melanoma patients treated with nivolumab plus ipilimumab (P <0.001). Early decreases in serum IL-8 levels were associated with longer overall survival in melanoma (P = 0.001) and NSCLC (P = 0.015) patients. Serum IL-8 levels also correctly reflected true response in three cancer patients presenting pseudoprogression. CONCLUSIONS: Changes in serum IL-8 levels could be used to monitor and predict clinical benefit from immune checkpoint blockade in melanoma and NSCLC patients.
BACKGROUND: Surrogate biomarkers of efficacy are needed for anti-PD1/PD-L1 therapy, given the existence of delayed responses and pseudo-progressions. We evaluated changes in serum IL-8 levels as a biomarker of response to anti-PD-1 blockade in melanoma and non-small-cell lung cancer (NSCLC) patients. PATIENTS AND METHODS: Metastatic melanoma and NSCLC patients treated with nivolumab or pembrolizumab alone or nivolumab plus ipilimumab were studied. Serum was collected at baseline; at 2-4 weeks after the first dose; and at the time-points of response evaluation. Serum IL-8 levels were determined by sandwich ELISA. Changes in serum IL-8 levels were compared with the Wilcoxon test and their strength of association with response was assessed with the Mann-Whitney test. Accuracy of changes in IL-8 levels to predict response was estimated using receiver operation characteristics curves. RESULTS: Twenty-nine melanoma patients treated with nivolumab or pembrolizumab were studied. In responding patients, serum IL-8 levels significantly decreased between baseline and best response (P <0.001), and significantly increased upon progression (P = 0.004). In non-responders, IL-8 levels significantly increased between baseline and progression (P = 0.013). Early changes in serum IL-8 levels (2-4 weeks after treatment initiation) were strongly associated with response (P <0.001). These observations were validated in 19 NSCLC patients treated with nivolumab or pembrolizumab (P = 0.001), and in 15 melanoma patients treated with nivolumab plus ipilimumab (P <0.001). Early decreases in serum IL-8 levels were associated with longer overall survival in melanoma (P = 0.001) and NSCLC (P = 0.015) patients. Serum IL-8 levels also correctly reflected true response in three cancer patients presenting pseudoprogression. CONCLUSIONS: Changes in serum IL-8 levels could be used to monitor and predict clinical benefit from immune checkpoint blockade in melanoma and NSCLC patients.
Authors: Stephen M Ansell; Alexander M Lesokhin; Ivan Borrello; Ahmad Halwani; Emma C Scott; Martin Gutierrez; Stephen J Schuster; Michael M Millenson; Deepika Cattry; Gordon J Freeman; Scott J Rodig; Bjoern Chapuy; Azra H Ligon; Lili Zhu; Joseph F Grosso; Su Young Kim; John M Timmerman; Margaret A Shipp; Philippe Armand Journal: N Engl J Med Date: 2014-12-06 Impact factor: 91.245
Authors: Carlos Alfaro; Alvaro Teijeira; Carmen Oñate; Guiomar Pérez; Miguel F Sanmamed; Maria Pilar Andueza; Diego Alignani; Sara Labiano; Arantza Azpilikueta; Alfonso Rodriguez-Paulete; Saray Garasa; Juan P Fusco; Angela Aznar; Susana Inogés; Maria De Pizzol; Marcello Allegretti; Jose Medina-Echeverz; Pedro Berraondo; Jose L Perez-Gracia; Ignacio Melero Journal: Clin Cancer Res Date: 2016-03-08 Impact factor: 12.531
Authors: Jedd D Wolchok; Axel Hoos; Steven O'Day; Jeffrey S Weber; Omid Hamid; Celeste Lebbé; Michele Maio; Michael Binder; Oliver Bohnsack; Geoffrey Nichol; Rachel Humphrey; F Stephen Hodi Journal: Clin Cancer Res Date: 2009-11-24 Impact factor: 12.531
Authors: Paul T Nghiem; Shailender Bhatia; Evan J Lipson; Ragini R Kudchadkar; Natalie J Miller; Lakshmanan Annamalai; Sneha Berry; Elliot K Chartash; Adil Daud; Steven P Fling; Philip A Friedlander; Harriet M Kluger; Holbrook E Kohrt; Lisa Lundgren; Kim Margolin; Alan Mitchell; Thomas Olencki; Drew M Pardoll; Sunil A Reddy; Erica M Shantha; William H Sharfman; Elad Sharon; Lynn R Shemanski; Michi M Shinohara; Joel C Sunshine; Janis M Taube; John A Thompson; Steven M Townson; Jennifer H Yearley; Suzanne L Topalian; Martin A Cheever Journal: N Engl J Med Date: 2016-04-19 Impact factor: 91.245
Authors: Roxana S Dronca; Xin Liu; Susan M Harrington; Lingling Chen; Siyu Cao; Lisa A Kottschade; Robert R McWilliams; Matthew S Block; Wendy K Nevala; Michael A Thompson; Aaron S Mansfield; Sean S Park; Svetomir N Markovic; Haidong Dong Journal: JCI Insight Date: 2016-05-05
Authors: Max Hardy-Werbin; Pedro Rocha; Oriol Arpi; Álvaro Taus; Lara Nonell; Xavier Durán; Xavier Villanueva; Deborah Joseph-Pietras; Luke Nolan; Sarah Danson; Richard Griffiths; Miguel Lopez-Botet; Ana Rovira; Joan Albanell; Christian Ottensmeier; Edurne Arriola Journal: Oncoimmunology Date: 2019-03-27 Impact factor: 8.110
Authors: Michalis Mastri; Christina R Lee; Amanda Tracz; Robert S Kerbel; Melissa Dolan; Yuhao Shi; John M L Ebos Journal: Mol Cancer Ther Date: 2018-04-25 Impact factor: 6.261
Authors: Jessica E Hawley; Samuel Pan; William D Figg; Zoila A Lopez-Bujanda; Jonathan D Strope; David H Aggen; Matthew C Dallos; Emerson A Lim; Mark N Stein; Jianhua Hu; Charles G Drake Journal: Prostate Date: 2020-01-03 Impact factor: 4.104